Target intelligence / Profile preview

SNCAIP antisense RNA 3 (SNCAIP-AS3)

Target
SNCAIP-AS3
Molecular classification
Other, Long non-coding RNA (lncRNA), Natural antisense transcript (NAT)
01

Overview

SNCAIP antisense RNA 3 (SNCAIP-AS3) is a long non-coding RNA classified as a natural antisense transcript (NAT) arising from the SNCAIP locus[1]. It is not a receptor, enzyme, or traditional druggable target, but rather regulates gene expression, most likely in cis, at the RNA level by mechanisms common to antisense RNAs such as interference with transcription, modulation of splicing, and/or regulation of mRNA stability[3][4][6]. There is limited functional characterization of SNCAIP-AS3 specifically; most published data focus on related antisense RNAs at the SNCA or SNCAIP loci. Currently, SNCAIP-AS3 does not have a direct, validated role as a therapeutic target, nor are there any known drug interactions or established roles in disease[1]. The target appears to be included due to mistaken identity or lack of target validation (it is not a protein, not a therapeutic target, and evidence for biological function is sparse). Additional context and justifications: - SNCAIP-AS3 is annotated as a non-coding RNA; no evidence suggests it encodes a functional protein or is a pharmacological target[1]. - "Antisense RNA" molecules such as SNCAIP-AS3 can regulate their sense gene via transcriptional interference, RNA duplex formation, chromatin remodeling, or modulation of mRNA stability[3][4][6]. - SNCAIP-AS3 does not appear as a known drug target in pharmacological databases, and no drugs are reported to interact with it. - Related natural antisense transcripts (e.g., SNCA-AS1) have shown involvement in neuronal functions and neurodegenerative disease models, but SNCAIP-AS3's specific role is not established. - SNCAIP-AS3 is sometimes confused with protein-coding genes or mistakenly labeled as "hypothetical protein MGC32805," but no protein product has been verified. In summary, SNCAIP-AS3 is a poorly characterized non-coding antisense transcript, not a validated therapeutic target, and its inclusion in a target list is most likely an error or the result of mistaken data interpretation[1].

Other names
MGC32805CTC-210G5.1hypothetical protein MGC32805SNCAIP-AS3
02

Biological functions

Regulation of gene expressionModulation of transcriptionPotential involvement in synapse biology (by analogy with related NATs)
03

Disease associations

Other (no direct disease association established for SNCAIP-AS3; by analogy, related SNCA antisense RNAs are implicated in neurodegeneration)

Beyond the preview

Go deeper on SNCAIP antisense RNA 3 (SNCAIP-AS3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNCAIP antisense RNA 3 (SNCAIP-AS3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call